Windlas BiotechNSE:WINDLAS -0.56%86 Interest Coverage is 11.72 as of Mar. 2026, which is 47% below its 10-year median of 21.99. GuruFocus rates NSE:WINDLAS with a GF Score™ of 86/100 and a GF Value™ of ₹936.98 (Fairly Valued). The stock has 1 warning sign investors should review. Among 684 Drug Manufacturers companies, Windlas Biotech ranks better than 54.24% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Windlas Biotech's
Operating Income
for the
three
months ended in Mar. 2026 was ₹173 Mil. Windlas Biotech's Interest Expense for the
three
months ended in Mar. 2026 was ₹-15 Mil.
Windlas Biotech's interest coverage for the quarter that ended in Mar. 2026 was 11.72.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Windlas Biotech's Interest Coverage or its related term are showing as below:
NSE:WINDLAS'
s Interest Coverage Range Over the Past 10 Years
Min: 6.26 Med: 21.99 Max: 60.82
Current: 15.33
NSE:WINDLAS's Interest Coverage is ranked better than 54.24% of 684
companies
in the Drug Manufacturers industry
Industry Median: 12.765
vs NSE:WINDLAS: 15.33
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Windlas Biotech Interest Coverage Related Terms
Windlas Biotech Interest Coverage Historical Data
* Premium members only.
The historical data trend for Windlas Biotech's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Drug Manufacturers - Specialty & Generic subindustry, Windlas Biotech's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Windlas Biotech Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Windlas Biotech's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Windlas Biotech's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Windlas Biotech (NSE:WINDLAS) has a Interest Coverage of 11.72 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Windlas Biotech and its competitors. This is 47% below median its historical median of 21.99. Over the past decade, Windlas Biotech's Interest Coverage has ranged from 6.26 to 60.82. According to the industry distribution chart, Windlas Biotech ranks #313 out of 684 companies in the Drug Manufacturers industry, placing it in the top 45.8%.
Is Windlas Biotech's Interest Coverage too high?
Windlas Biotech's current Interest Coverage of 11.72 is 47% below median its 10-year median of 21.99. Over the past 10 years, this metric has ranged from a low of 6.26 to a high of 60.82. The Drug Manufacturers industry median Interest Coverage is 12.77. Windlas Biotech's value of 11.72 is 8.2% below this industry median. Based on the distribution chart, Windlas Biotech ranks #313 out of 684 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Windlas Biotech has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Windlas Biotech's Interest Coverage compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Windlas Biotech ranks #313 out of 684 companies for Interest Coverage. This puts Windlas Biotech in the upper half of its industry. The industry median Interest Coverage is 12.77. Windlas Biotech's value of 11.72 is 8.2% below this benchmark. Historically, Windlas Biotech's own Interest Coverage has ranged from 6.26 to 60.82 over the past decade. While the company's 10-year median is 21.99 vs. the industry median of 12.77, Windlas Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.77, based on 684 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Windlas Biotech's current Interest Coverage of 11.72 is 8.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Windlas Biotech and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Windlas Biotech's current Interest Coverage is 11.72, which is 47% below median its own 10-year median of 21.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Windlas Biotech stock overvalued right now?
Based on GuruFocus' analysis, Windlas Biotech (NSE:WINDLAS) is currently considered Fairly Valued. The stock's GF Value™ is ₹936.98, compared to a current price of ₹859.00 — trading 8.3% below its estimated fair value. The current Interest Coverage is 11.72, which is 47% below median its 10-year median of 21.99 and 8.2% below the Drug Manufacturers industry median of 12.77. Windlas Biotech's overall GF Score™ is 86/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Windlas Biotech (NSE:WINDLAS), the current Interest Coverage is 11.72 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Windlas Biotech (NSE:WINDLAS) Overvalued in 2026?
Based on GuruFocus' analysis, Windlas Biotech stock appears to be undervalued.
The current stock price of ₹859.00 is trading 8.3% below its estimated GF Value™ of ₹936.98.
GuruFocus considers Windlas Biotech to be Fairly Valued.
Key valuation signals for NSE:WINDLAS:
Interest Coverage: 11.72 (47% below median its 10-year median of 21.99)
GF Value™: ₹936.98 vs. price of ₹859.00 (8.3% below fair value)
Industry Position: 8.2% below the Drug Manufacturers median (#313 of 684)
No single metric tells the full story. See the NSE:WINDLAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Windlas Biotech Ltd is a pharmaceutical formulation contract development and manufacturing organization. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.
86GF Score
Get the complete analysis for NSE:WINDLAS
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:WINDLAS has been successfully added to your 
